Findings

DEMO DATA

Interpretation of the current audit cycle — what the data shows, where practice is good, and where gaps exist.

Areas of good practice
AKI warning stage or suspected AKI documented.
100%
Likely cause or contributing factors for AKI documented.
100%
AKI stage progression, stability or recovery documented.
91.7%
Priority gaps
Post-discharge kidney function monitoring plan documented where relevant. (target ≥ 85%)
48.3%
Critical care, outreach or urgent escalation completed where indicated. (target ≥ 90%)
50%
Patient advice about kidney health, medicines or follow-up documented where appropriate. (target ≥ 80%)
51.7%
Obstruction considered where clinically relevant. (target ≥ 85%)
53.3%
Clinical review completed within the locally agreed timeframe for AKI stage and clinical condition. (target ≥ 90%)
58.3%
Dose adjustment considered for renally cleared medicines where relevant. (target ≥ 85%)
58.3%
Discharge summary includes AKI episode and follow-up plan where relevant. (target ≥ 90%)
65%
Senior review completed where required by local policy. (target ≥ 90%)
69.6%
Urine output documented or urine output monitoring commenced where appropriate. (target ≥ 90%)
70%
Nephrotoxic, renally cleared or AKI-relevant medicines reviewed. (target ≥ 90%)
70%
Hyperkalaemia checked or managed where relevant. (target ≥ 90%)
71.7%
Medication review completed. (target ≥ 90%)
76.7%
Sepsis considered where clinically relevant. (target ≥ 90%)
76.7%
Renal referral completed where indicated by local policy. (target ≥ 90%)
80%
Fluid management plan documented where clinically relevant. (target ≥ 90%)
81.7%
Repeat creatinine / U&E monitoring plan documented. (target ≥ 90%)
85%
AKI recognised and documented by the clinical team. (target ≥ 90%)
86.7%
Volume status assessed. (target ≥ 90%)
88.3%
User commentary
Editable interpretation for reports and governance meetings.
Governance & safety implications
Any immediate AKI, hyperkalaemia, obstruction, sepsis, contrast or medication safety concern identified during this audit must be escalated through local clinical, renal, pharmacy, critical care and governance pathways. This tool does not replace local escalation processes.